On Invalid Date, Affimed Nv (NASDAQ: AFMD) reported Q1 2023 earnings per share (EPS) of -$0.23, up 48.05% year over year. Total Affimed Nv earnings for the quarter were -$34.76 million. In the same quarter last year, Affimed Nv's earnings per share (EPS) was -$0.15.
As of Q2 2023, Affimed Nv's earnings has grown year over year. Affimed Nv's earnings in the past year totalled -$111.34 million.
What was AFMD's revenue last quarter?
On Invalid Date, Affimed Nv (NASDAQ: AFMD) reported Q1 2023 revenue of $4.90 million up 44.28% year over year. In the same quarter last year, Affimed Nv's revenue was $8.80 million.
What was AFMD's revenue growth in the past year?
As of Q2 2023, Affimed Nv's revenue has grown 2% year over year. This is 67.6 percentage points lower than the US Biotechnology industry revenue growth rate of 69.59%. Affimed Nv's revenue in the past year totalled $41.60 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.